Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in clinical immunosuppression.

B Watschinger1, C Wenter, D Demetriou

  • 1Department of Internal Medicine III Renal Division, University of Vienna, Austria.

Kidney & Blood Pressure Research
|October 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Supportive therapy in pulmonary arterial hypertension].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

[Hypertension and nutrition. Position paper of the Austrian Nutrition Society].

Herz·2012
Same author

Unusual microbes in asthma exacerbation: Alcaligenes xylosoxidans and Leishmania.

The European respiratory journal·2009
Same author

Cartilage biomarkers in hemodialysis patients and the effect of beta2-microglobulin on articular chondrocytes.

Osteoarthritis and cartilage·2008
Same author

Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial.

Kidney international·2006
Same author

The malononitrilamide FK778 inhibits activation of NF-kappaB in human dendritic cells.

Transplantation proceedings·2005
Same journal

Epidemiology and multimorbidity in hemodialysis patients at a tertiary care center in northern Mexico: implications for hospital-based adverse outcomes.

Kidney & blood pressure research·2026
Same journal

The inflammatory milieu exacerbates Anemia of CKD:  From the gut-kidney axis to bone marrow hematopoiesis inhibition.

Kidney & blood pressure research·2026
Same journal

Cystine-binding medication is poorly accessible for the treatment of cystinuria.

Kidney & blood pressure research·2026
Same journal

Infective endocarditis-associated glomerulonephritis caused by Streptococcus cristatus: A Case Report.

Kidney & blood pressure research·2026
Same journal

Simplified Subjective Global Assessment at Hemodialysis Initiation and Its Association with 2-Year Mortality and Hospitalization.

Kidney & blood pressure research·2026
Same journal

Long-Term Betaine Supplementation Increases Creatinine Clearance and Upregulates MAS and AT2 Receptor Expression in Spontaneously Hypertensive Rat Kidneys.

Kidney & blood pressure research·2026
See all related articles

New immunosuppressants reduce kidney transplant rejection, but personalized medicine is key. Further trials are needed to tailor treatments for optimal long-term patient and allograft survival.

Area of Science:

  • Nephrology
  • Transplantation Medicine
  • Immunology

Background:

  • Recent advancements in immunosuppressant drugs have improved outcomes for kidney transplant recipients.
  • Despite progress, acute rejection episodes remain a concern, and achieving full graft tolerance is the ultimate goal.

Purpose of the Study:

  • To highlight the need for personalized immunosuppression strategies in kidney transplantation.
  • To emphasize the importance of tailoring drug regimens to individual patient needs for better long-term results.

Main Methods:

  • This study is a review and discussion of current immunosuppressive strategies in kidney transplantation.
  • It synthesizes existing knowledge on drug efficacy and patient variability.

Main Results:

Related Experiment Videos

  • Newer immunosuppressants have demonstrably reduced acute rejection rates post-kidney transplant.
  • Patient and allograft survival can be optimized by individualizing immunosuppressive protocols.

Conclusions:

  • While new drugs are beneficial, they do not eliminate the need for tailored immunosuppression.
  • Further prospective, controlled trials are essential to identify patient subgroups that benefit most from specific immunosuppressive protocols, thereby enhancing long-term allograft and patient survival.